3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Endometrial Hyperplasia
2
Breast Neoplasms
2
Venous Thrombosis
1
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
42
Nivolumab
13
Carboplatin
11
Cyclophosphamide
10
olaparib
7
Paclitaxel
7
Ipilimumab
7
fludarabine
6
Gemcitabine
6
durvalumab
5
lenvatinib
4
cemiplimab
4
atezolizumab
4
Specimen Handling
4
Oxaliplatin
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Fulvestrant
4
Fluorouracil
4
Cisplatin
4
Bevacizumab
4
veliparib
3
spartalizumab
3
sacituzumab govitecan
3
liposomal doxorubicin
3
avelumab
3
aldesleukin
3
Taxes
3
Interleukin-2
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Atorvastatin
×
Gynecologic
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn